• Explore /
  • Poster
  • / Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in non-small-cell lung cancer (NSCLC) with c-MET<em> </em>exon 14 skipping mutations (<em>MET</em>ex14).

Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in non-small-cell lung cancer (NSCLC) with c-MET exon 14 skipping mutations (METex14).

Abstract Poster

Authors

null

Mariana da Rocha Almeida Brandao

Medical Oncology Department, Institut Jules Bordet and l’Université Libre de Bruxelles (U.L.B), Brussels, Belgium

Mariana da Rocha Almeida Brandao , Jon Zugazagoitia , Anne-Marie C. Dingemans , Michaël Duruisseaux , Pauline Parent , Oscar Juan-Vidal , Alexander I. Spira , Cecile Vicier , Gerard Zalcman , Ben Barasa , Chris Yan , Petra Doze , Andrew K. Joe , Gianluca Laus , Enriqueta Felip

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT04868877

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 8583)

DOI

10.1200/JCO.2024.42.16_suppl.8583

Abstract #

8583

Poster Bd #

447

Abstract Disclosures

Similar Posters

First Author: Jay M. Lee

First Author: Helena Alexandra Yu

First Author: Jonathan N. Priantti

First Author: Alexander I. Spira